1,530
Views
14
CrossRef citations to date
0
Altmetric
Original research

The immune molecular landscape of the B7 and TNFR immunoregulatory ligand–receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications

, , , , , , & show all
Article: e1288329 | Received 28 Nov 2016, Accepted 23 Jan 2017, Published online: 30 Mar 2017

References

  • Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975; 53:27-42; PMID:238498; http://dx.doi.org/10.1038/icb.1975.3
  • Assal A, Kaner J, Pendurti G, Zang X. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015; 7:1169-86; PMID:26567614; http://dx.doi.org/10.2217/imt.15.78
  • Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 2016; 44:955-72; PMID:27192563; http://dx.doi.org/10.1016/j.immuni.2016.05.002
  • Ward-Kavanagh LK, Lin WW, Sedy JR, Ware CF. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity 2016; 44:1005-19; PMID:27192566; http://dx.doi.org/10.1016/j.immuni.2016.04.019
  • Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA. An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest 2013; 123:580-93; PMID:23281398; http://dx.doi.org/10.1172/JCI65013
  • Wang L, Kang FB, Shan BE. B7-H3-mediated tumor immunology: friend or foe? Int J Cancer 2014; 134:2764-71; PMID:24013874; http://dx.doi.org/10.1002/ijc.28474
  • Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM, Tsuchiya H. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193:839-46; PMID:11283156; http://dx.doi.org/10.1084/jem.193.7.839
  • Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013; 34:556-63; PMID:23954143; http://dx.doi.org/10.1016/j.it.2013.07.003
  • Yao S, Zhu Y, Zhu G, Augustine M, Zheng L, Goode DJ, Broadwater M, Ruff W, Flies S, Xu H et al. B7-H2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34:729-40; PMID:21530327; http://dx.doi.org/10.1016/j.immuni.2011.03.014
  • Textor S, Bossler F, Henrich KO, Gartlgruber M, Pollmann J, Fiegler N, Arnold A, Westermann F, Waldburger N, Breuhahn K et al. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Oncoimmunology 2016; 5:e1116674; PMID:27622013; http://dx.doi.org/10.1080/2162402X.2015.1116674
  • Jung K, Choi I. Emerging Co-signaling networks in T cell immune regulation. Immune Netw 2013; 13:184-93; PMID:24198743; http://dx.doi.org/10.4110/in.2013.13.5.184
  • Clouthier DL, Watts TH. TNFRs and control of chronic LCMV infection: implications for therapy. Trends Immunol 2015; 36:697-708; PMID:26481667; http://dx.doi.org/10.1016/j.it.2015.09.005
  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin 2015; 65:87-108; PMID:25651787; http://dx.doi.org/10.3322/caac.21262
  • Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359:1143-54; PMID:18784104; http://dx.doi.org/10.1056/NEJMra0707975
  • Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35; PMID:20530316; http://dx.doi.org/10.1056/NEJMoa0912217
  • Mandal R, Senbabaoglu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016; 1:e89829; PMID:27777979; http://dx.doi.org/10.1172/jci.insight.89829
  • Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ. OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment. Oral Oncol 2016; 52:1-10; PMID:26614363; http://dx.doi.org/10.1016/j.oraloncology.2015.11.009
  • Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375(19):1856-1867; PMID:27718784; http://dx.doi.org/10.1056/NEJMoa1602252
  • Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17:956-65; PMID:27247226; http://dx.doi.org/10.1016/S1470-2045(16)30066-3
  • Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-4; PMID:22588877; http://dx.doi.org/10.1158/2159-8290.CD-12-0095
  • Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6:pl1; PMID:23550210; http://dx.doi.org/10.1126/scisignal.2004088
  • Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, Tamada K, Pardoll DM, Chen L. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007; 110:180-5; PMID:17289811; http://dx.doi.org/10.1182/blood-2006-11-060087
  • Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111:3635-43; PMID:18223165; http://dx.doi.org/10.1182/blood-2007-11-123141
  • Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One 2015; 10:e0142656; PMID:26562534; http://dx.doi.org/10.1371/journal.pone.0142656
  • Mukaigawa T, Hayashi R, Hashimoto K, Ugumori T, Hato N, Fujii S. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol 2016; 114:36-43; PMID:27111278; http://dx.doi.org/10.1002/jso.24266
  • Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73:1733-41; PMID:23288508; http://dx.doi.org/10.1158/0008-5472.CAN-12-2384
  • Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
  • Partlova S, Boucek J, Kloudova K, Lukesova E, Zabrodsky M, Grega M, Fučíková J, Truxová I, Tachezy R, Špíšek R et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 2015; 4:e965570; PMID:25949860;http://dx.doi.org/10.4161/21624011.2014.965570
  • Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL. CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients. Clin Cancer Res 2016; 23(3):707-716; PMID:27496866; http://dx.doi.org/10.1158/1078-0432.CCR-16-0879
  • Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013; 45:791-8; PMID:23685749; http://dx.doi.org/10.1038/ng.2643
  • Morris LG, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS et al. The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform. JAMA Oncol 2016; 3(2):244-255; PMID:27442865; http://dx.doi.org/10.1001/jamaoncol.2016.1790
  • Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011; 7:539; PMID:21988835; http://dx.doi.org/10.1038/msb.2011.75
  • Li W, Cowley A, Uludag M, Gur T, McWilliam H, Squizzato S, Park YM, Buso N, Lopez R. The EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic Acids Res 2015; 43:W580-4; PMID:25845596; http://dx.doi.org/10.1093/nar/gkv279
  • McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, Cowley AP, Lopez R. Analysis tool web services from the EMBL-EBI. Nucleic Acids Res 2013; 41:W597-600; PMID:23671338; http://dx.doi.org/10.1093/nar/gkt376
  • The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576-82; PMID:25631445; http://dx.doi.org/10.1038/nature14129

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.